Bullfrog AI

Update in progress

BFRG (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryHealth Information Services

Bullfrog AI Holdings, Inc. is a U.S. digital biopharmaceutical company that uses AI/ML to analyze medical data. Its bfLEAP platform supports preclinical and clinical data analysis for biotech and pharma clients. It develops BF-222 (mebendazole formulation) for glioblastoma in Phase 1, BF-223 (mebendazole prodrug) in preclinical glioblastoma, and BF-114 for obesity and liver diseases in discovery. It licenses with George Washington University and Johns Hopkins University and collaborates with the LIBD. Founded 2017, based in Gaithersburg, Maryland.

Company score

Sentiment: 0.47; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.09; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.13; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.00; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.23; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive